Cutting edge: A novel role for Fas ligand in facilitating antigen acquisition by dendritic cells
Cutting edge: A novel role for Fas ligand in facilitating antigen acquisition by dendritic cells
复制标题
DOI：
10.4049/jimmunol.169.5.2241
复制
发表时间：
2002-09-01
影响因子：
4.4
通讯作者：
Tagawa, M
中科院分区：
文献类型：
--
作者：
Tada, Y;O-Wang, J;Tagawa, M
发现表达Fas配体（FasL）的肿瘤细胞有效地介导共接种的FasL阴性亲本细胞的排斥，而对组织学上不同的肿瘤细胞的生长没有影响。这些观察结果表明，FasL诱导特异性免疫反应，对来自FasL-轴承肿瘤的Ag，并建议在肿瘤Ag呈递FasL的可能作用。事实上，表达FasL的肿瘤细胞可以有效地与树突状细胞（DC）相互作用，并且这种相互作用需要肿瘤上的膜结合的FasL和DC上的Fas的表达。此外，与表达FasL的肿瘤共培养的DC能够在体内引发肿瘤特异性免疫应答，表明DC在Fas/FasL介导的DC-肿瘤接触期间获得肿瘤抗原。这些结果确定了FasL在增强肿瘤-DC相互作用和随后的DC获得肿瘤Ag中的新作用，并表明表达FasL的肿瘤细胞可用于产生肿瘤特异性DC疫苗。
Fas ligand (FasL)-expressing tumor cells are found to effectively mediate rejection of the coinoculated FasL negative parental cells while having no effect on the growth of histologically distinct tumor cells. These observations indicate that FasL induces a specific immune response against Ag derived from FasL-bearing tumors and suggest a possible role for FasL in tumor Ag presentation. Indeed, tumor cells expressing FasL can efficiently interact with dendritic cells (DCs) and this interaction requires the expression of membrane-bound FasL on tumors and Fas on DCs. Moreover, DCs cocultured with FasL-expressing tumors are able to elicit a tumor-specific immune response in vivo, suggesting that DCs acquire tumor Ag during the Fas/FasL-mediated DC-tumor contact. These results identify a novel role for FasL in augmenting tumor-DC interactions and subsequent tumor Ag acquisition by DCs, and suggest that FasL-expressing tumor cells could be used to generate tumor-specific DC vaccines.